Blood-Based Biomarker Test May Predict Or Rule Out Alzheimer’s Disease-Related Pathology, Study Finds

Healio (2/6, Herpen) reports that the PrecivityAD2 blood biomarker, “a blood-based biomarker test, may be a reliable method for predicting or ruling out Alzheimer’s disease-related pathology and subsequently for assisting clinicians in formulating a treatment plan for patients, according to new research.” This test “combines plasma amyloid-beta 42/40 and the p-tau217/np-tau217 ratios to create an Amyloid Probability Score 2, which assists in predicting the likelihood of brain amyloid plaques indicative of AD pathology.” The findings were published in Diagnostics.